AR008559A1 - Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo - Google Patents

Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo

Info

Publication number
AR008559A1
AR008559A1 ARP980101391A ARP980101391A AR008559A1 AR 008559 A1 AR008559 A1 AR 008559A1 AR P980101391 A ARP980101391 A AR P980101391A AR P980101391 A ARP980101391 A AR P980101391A AR 008559 A1 AR008559 A1 AR 008559A1
Authority
AR
Argentina
Prior art keywords
pps
pharmaceutically acceptable
acceptable salt
pentosanpolysulfate
approximately
Prior art date
Application number
ARP980101391A
Other languages
English (en)
Original Assignee
Secretaria Departamento De Salud Y Servicios Humanos The United States Of America Representada Por L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25283204&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR008559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Secretaria Departamento De Salud Y Servicios Humanos The United States Of America Representada Por L filed Critical Secretaria Departamento De Salud Y Servicios Humanos The United States Of America Representada Por L
Publication of AR008559A1 publication Critical patent/AR008559A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uso de pentosanpolisulfato (PPS) o de una sal farmacéuticamente aceptable del mismo, para preparar una composicion farmacéutica util para eltratamiento de un paciente mamífero que sufre una enfermedad cicatrizante vascular progresiva cronica(CPVD), particularmente una enfermedadarterioesclerotica como la aterioesclerosis, que tiene por objeto detener el progreso de la misma y causar la resolucion o disminucion de las lesionesy cicatrices ya formadas. De acuerdo a dichotratamiento se administra al paciente una composicion farmacéutica que contiene una cantidad efectiva depentosanpolisulfato (PPS) o de una sal farmacéuticamente aceptable del mismo. Se prefiere la vía oral de administracion, oscilandola dosis di ariatotal de PPS o sal de PPS aproximadamente entre 5 y 30 mg/kg. de peso, o aproximadamente entre 350 y 2000 mg en pacientes humanos adultos.
ARP980101391A 1997-04-16 1998-03-26 Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo AR008559A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/840,777 US20010005720A1 (en) 1995-06-07 1997-04-16 Method of treating chronic progressive vascular scarring diseases

Publications (1)

Publication Number Publication Date
AR008559A1 true AR008559A1 (es) 2000-01-19

Family

ID=25283204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101391A AR008559A1 (es) 1997-04-16 1998-03-26 Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo

Country Status (17)

Country Link
US (1) US20010005720A1 (es)
EP (1) EP0986392A4 (es)
JP (1) JPH1149802A (es)
KR (1) KR20010006511A (es)
CN (1) CN1259871A (es)
AR (1) AR008559A1 (es)
AU (1) AU750182B2 (es)
BR (1) BR9809396A (es)
CA (1) CA2285950A1 (es)
HU (1) HUP0003256A3 (es)
IL (1) IL132389A0 (es)
NO (1) NO995024L (es)
NZ (1) NZ500527A (es)
SK (1) SK142599A3 (es)
TW (1) TW557213B (es)
WO (1) WO1998046237A1 (es)
ZA (1) ZA982246B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039709A1 (en) * 2004-10-01 2006-04-13 Keryx Biopharmaceuticals, Inc. Methods using glycosaminoglycans for the treatment of kidney disease
WO2010103837A1 (ja) 2009-03-11 2010-09-16 ゼライス株式会社 アテローム性動脈硬化症の進行抑制薬・予防薬・血中コレステロール低下薬・機能性食品・特定保健用食品
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
MX2020002288A (es) 2016-08-31 2020-07-14 Oji Holdings Corp Metodo de produccion para xilooligosacarido acido y xilooligosacarido acido.
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
KR20240023711A (ko) 2017-05-31 2024-02-22 오지 홀딩스 가부시키가이샤 보습 외용제
MX2020002726A (es) 2017-09-12 2020-07-20 Oji Holdings Corp Polisulfato de pentosan y metodo para producir polisulfato de pentosan.
HUE062342T2 (hu) 2017-12-20 2023-10-28 Oji Holdings Corp Pentozán-poliszulfát, valamint pentozán-poliszulfátot tartalmazó gyógyszerek
WO2023070164A1 (en) * 2021-10-28 2023-05-04 Paradigm Biopharmaceuticals Ltd Treatment of heart failure with preserved ejection fraction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
HUP0003256A2 (hu) 2001-02-28
JPH1149802A (ja) 1999-02-23
US20010005720A1 (en) 2001-06-28
NZ500527A (en) 2001-10-26
CA2285950A1 (en) 1998-10-22
AU750182B2 (en) 2002-07-11
AU7248298A (en) 1998-11-11
HUP0003256A3 (en) 2001-12-28
WO1998046237A1 (en) 1998-10-22
CN1259871A (zh) 2000-07-12
KR20010006511A (ko) 2001-01-26
TW557213B (en) 2003-10-11
NO995024L (no) 1999-12-13
BR9809396A (pt) 2000-06-13
EP0986392A1 (en) 2000-03-22
NO995024D0 (no) 1999-10-15
IL132389A0 (en) 2001-03-19
ZA982246B (en) 1998-09-17
SK142599A3 (en) 2001-12-03
EP0986392A4 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BR9909192A (pt) Preparações galênicas de meloxicam para administração oral
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
BR0008039A (pt) Combinações de formoterol e um sal de tiotrópio
CO5261582A1 (es) Composiciones de valdecoxib
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
JP2002528502A5 (es)
AR008559A1 (es) Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
KR970025615A (ko) 암 전이 억제제
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
CL2004000304A1 (es) Uso del acido 4-[1-hidroxi-4-[4-hidroxidifenilmetil)-1-piperidinil]butil]-alfa, alfa-dimetilbenceno acetico o una sal farmaceuticamente aceptable del mismo, para la preparacion de un medicamento util como antihistaminico, en pacientes que padecen un
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
GB9023701D0 (en) Medical treatment
KR890004705A (ko) 항바이러스성 제제
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure